WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Anticoagulant_Master_CMAP_v2, Subgroups hasObservation Concomitant medications, Concepts (e.g. Subgroup, NCB) are denoted by solid round-edged rectangle, Primary efficacy endpoints are denoted by bold font, Safety endpoint is the intersection of Observation or Assessment, Safety endpoint is the intersection of Physiolgoical Process, Net clinical benefit (NCB) hasObservation CRF: Myocardial infarction (MI), Therapeutic Efficacy Point is the intersection of Observation or Assessment, Observation or Assessment is used to monitor the state of Physiolgoical Process, Secondary efficacy endpoints hasObservation CRF: Pulmonary embolism (PE), Secondary efficacy endpoints hasObservation Additional efficacy endpoints, Subgroups hasObservation Demographics, Liver function test (LFT) hasMeasurementTime Defined timepoints, Repeated concepts/instances (e.g. Stroke, Death) are denoted by dotted outline, Main concept groups (e.g. Safety endpoints) are denoted by Larger bold font with thicker outline, Therapeutic Efficacy Point is the intersection of Physiolgoical Process, Net clinical cost (NCC) hasObservation CRF: Myocardial infarction (MI), CRF: Stroke hasMeasurementMethodology Occurrence rate, CRF: Non-CNS systemic embolism (SEE) hasMeasurementMethodology Occurrence rate, Secondary efficacy endpoints hasObservation CRF: Death, Hepatotoxicity hasOutcomeAssessment Liver function test (LFT)